Detalhe da pesquisa
1.
Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort.
Blood
; 139(22): 3278-3289, 2022 06 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-35196370
2.
Polatuzumab vedotin plus bendamustine and rituximab or obinutuzumab in relapsed/refractory follicular lymphoma: a phase Ib/II study.
Haematologica
; 109(4): 1194-1205, 2024 Apr 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37767550
3.
Impact and utility of follicular lymphoma GELF criteria in routine care: an Australasian Lymphoma Alliance study.
Haematologica
; 2024 Mar 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-38450504
4.
Rethinking the transfusion pathway in myelodysplastic syndromes: Study protocol for a novel randomized feasibility n-of-1 trial of weekly-interval red cell transfusion in myelodysplastic syndromes.
Transfusion
; 64(2): 236-247, 2024 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-38214417
5.
Attitudes towards COVID-19 vaccination in adults with haematological malignancies.
Acta Haematol
; 2024 Jan 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-38290477
6.
Hematologic Malignancy: Who Cares in the End? A Retrospective Cohort Study of Markers of Quality End-of-Life Care.
J Natl Compr Canc Netw
; 21(8): 813-820.e1, 2023 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37549908
7.
High risk of infection in 'real-world' patients receiving ibrutinib, idelalisib or venetoclax for mature B-cell leukaemia/lymphoma.
Eur J Haematol
; 110(5): 540-547, 2023 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-36656100
8.
Clinical characteristics of Australian treatment-naïve patients with classical Hodgkin lymphoma from the lymphoma and related diseases registry.
Eur J Haematol
; 110(4): 386-395, 2023 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-36539351
9.
Occupational exposure to extremely low-frequency magnetic fields and follicular lymphoma risk: a family case-control study.
Occup Environ Med
; 80(10): 599-602, 2023 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37722828
10.
Australian data on the utilisation and duration on treatment of ibrutinib with a proton pump inhibitor in patients with relapsed or refractory chronic lymphocytic leukaemia.
Intern Med J
; 53(11): 2115-2118, 2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-37950615
11.
Chronic lymphocytic leukaemia Australasian consensus practice statement.
Intern Med J
; 53(9): 1678-1691, 2023 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37743239
12.
Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial.
Lancet Oncol
; 23(8): 1031-1043, 2022 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35810754
13.
Zanubrutinib for treatment-naïve and relapsed/refractory chronic lymphocytic leukaemia: long-term follow-up of the phase I/II AU-003 study.
Br J Haematol
; 196(5): 1209-1218, 2022 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-34915592
14.
Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions.
N Engl J Med
; 380(23): 2225-2236, 2019 Jun 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-31166681
15.
Zanubrutinib for the treatment of patients with Waldenström macroglobulinemia: 3 years of follow-up.
Blood
; 136(18): 2027-2037, 2020 10 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-32698195
16.
A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study.
Blood
; 136(18): 2038-2050, 2020 10 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-32731259
17.
Protocol for SARS-CoV-2 post-vaccine surveillance study in Australian adults and children with cancer: an observational study of safety and serological and immunological response to SARS-CoV-2 vaccination (SerOzNET).
BMC Infect Dis
; 22(1): 70, 2022 Jan 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-35057745
18.
Low mortality in vaccinated immunocompromised haematology patients infected with SARS-CoV-2.
Intern Med J
; 52(12): 2172-2175, 2022 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-36436197
19.
Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL.
Blood
; 134(11): 851-859, 2019 09 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-31340982
20.
An update of venetoclax and obinutuzumab in chronic lymphocytic leukemia.
Future Oncol
; 17(4): 371-387, 2021 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-33064021